BIO-TECHNE Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BIO-TECHNE Corporation on February 9, 2026, regarding events occurring on February 9, 2026, and February 11, 2026. The filing addresses significant executive leadership changes within the Diagnostics and Spatial Biology Segment.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms and employment agreements.
Material Changes
- Departure: Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment, is transitioning out of his role effective March 1, 2026. His employment was terminated without cause on February 9, 2026, making him eligible for severance benefits.
- Appointment: Mr. Steve Crouse, currently Senior Vice President of the Analytical Solutions Division, was appointed as the new President of the Diagnostics and Spatial Biology Segment, effective March 1, 2026.
Guidance, Outlook, and Compensation Details
The filing details the compensation package for the newly appointed President, Mr. Crouse, under an employment agreement commencing March 1, 2026:
- Base Salary: $505,000 annually.
- Cash Incentive: Target annual bonus of 75% of base salary, subject to performance standards.
- Initial Equity Grant (One-time):
- Time-vested stock options: ~$42,500 grant date value.
- Time-vested restricted stock units (RSUs): ~$42,500 grant date value.
- Performance-based RSUs: $85,000 grant date value at target (vesting contingent on FY2026-FY2028 goals).
- Annual Equity Grant (Recurring):
- Time-vested stock options: ~$300,000 grant date value.
- Time-vested RSUs: ~$300,000 grant date value.
- Performance-based RSUs: $600,000 grant date value at target.
- Severance Provisions: In the event of termination without Cause, Change in Control, or Good Reason, Mr. Crouse is entitled to one year of base salary, a prorated cash incentive, and one year of health insurance coverage.
Investor Verification Checklist
- Verify the specific performance metrics attached to the $85,000 initial and $600,000 annual performance-based RSU grants.
- Review the full Executive Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the transition timeline and interim leadership structure for the Diagnostics and Spatial Biology Segment between February 11 and March 1, 2026.
- Assess the impact of Dr. McManus's departure on the segment's strategic initiatives, given his prior role.